Back to Journals » Transplant Research and Risk Management » Volume 3

Critical appraisal of belatacept for prophylaxis of rejection in kidney transplant patients

Authors Martin S, Tsapepas, Gabardi S, Chandraker A

Published 12 April 2011 Volume 2011:3 Pages 65—75

DOI https://doi.org/10.2147/TRRM.S11538

Review by Single-blind

Peer reviewer comments 6


Spencer T Martin1, Demetra Tsapepas1, Steven Gabardi2–5, Anil Chandraker2,3
1
Department of Pharmacy, New York-Presbyterian Hospital, New York City, NY, USA; 2Harvard Medical School, Boston, MA, USA; 3Renal Division, 4Department of Pharmacy Services, 5Department of Transplant Surgery, Brigham and Women's Hospital, Boston, MA, USA

Abstract: Belatacept (LEA29Y) is an intravenous biologic for long-term maintenance immunosuppressive therapy in renal transplant recipients. It is currently being reviewed by the United States Food and Drug Administration (FDA) as a prophylactic therapy against acute cellular rejection (ACR) in de novo renal transplant recipients. To provide an in-depth review of the pharmacology, clinical efficacy, safety, and applications of belatacept, a MEDLINE database search was performed for all English-language articles evaluating the pharmacology and efficacy of belatacept, as well as abstracts from recent scientific meetings. Belatacept is a potent inhibitor of B7 binding to CD28, a potent T-cell co-stimulatory signal. The B7 ligands are found on the surface of antigen-presenting cells, specifically B7-1 (CD80) and B7-2 (CD86). CD80 and CD86 are essential ligands for CD28, a critical component of costimulation in the three-signal transplant model of T-cell activation. Belatacept has proven noninferiority compared with calcineurin-inhibitor (CNI)-based regimens in the incidence of patient and allograft survival. However, the incidence and severity of ACR has been shown to be increased in patients receiving belatacept therapy. Although rates of ACR are increased in patients receiving belatacept, an overall improvement in allograft function has been described with average improvements in glomerular filtration rates of up to 12–15 mL/min higher than CNI-based regimens. The side-effect profile of belatacept has been shown to be similar or improved compared with CNI therapy; however, the risk of malignancy, specifically post-transplant lymphoproliferative disorder is notably higher. Because of the marked increase in the risk of malignancy and ACR, approval of belatacept by the FDA will rely on more robust data from long-term follow-up of currently available data.

Keywords: renal transplantation, immunosuppression

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]